ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
BRIDGEWATER, N.J., Aug. 01, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that John Timberlake, President and Chief Executive Officer, and Erick Lucera, Chief Financial Officer, are scheduled to present at the Wedbush PacGrow Healthcare Conference. The Company will also participate in the Drug Delivery Technologies Panel moderated in part by Tao Levy, Managing Director Medical Devices Equity Research.
| Event: | Wedbush Drug Delivery Technologies Panel | |
| Date: | Tuesday, August 15, 2017 | |
| Time: | 11:30 a.m. EDT | |
| Location: | New York, NY | |
| Event: | Wedbush PacGrow Healthcare Conference Company Presentation | |
| Date: | Wednesday, August 16, 2017 | |
| Time: | 9:10 a.m. EDT | |
| Location: | New York, NY | |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contact: Robert E. Flamm, Ph.D. / Brian Johnston The Ruth Group 646-536-7017 / 7028 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas / Cari Randall The Ruth Group 508-280-6592 / 646-536-7002 [email protected]
